A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies
Recruiting in Palo Alto (17 mi)
+1 other location
Overseen bySunil Singhal, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: OncoNano Medicine, Inc.
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This Phase 2 study is an open-label, single-arm trial where each patient is his/her own "intrapatient" control. All patients will receive a single dose of pegsitacianine prior to standard of care surgery.
Eligibility Criteria
Inclusion Criteria
Biopsy confirmed diagnosis, or a high clinical suspicion of a lung malignancy based on MRI, CT and/or PET imaging
Treatment Details
Interventions
- Pegsitacianine (Fluorescence Imaging Agent)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Fluorescence imaging with pegsitacianineExperimental Treatment2 Interventions
Pegsitacianine 1 mg/ml infused 24-72 hours prior to surgery.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Hospital of the University of PennsylvaniaPhiladelphia, PA
The University of Texas MD Anderson Cancer CenterHouston, TX
Loading ...
Who Is Running the Clinical Trial?
OncoNano Medicine, Inc.Lead Sponsor